Skip to content

Nebulized Colistin for Hospital-Acquired Pneumonia

Efficacy and Safety of Nebulized Colistin for Adjunctive Therapy of Hospital-Acquired Pneumonia Caused by Gram Negative Bacteria

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00920270
Enrollment
140
Registered
2009-06-15
Start date
2006-06-30
Completion date
Unknown
Last updated
2009-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Keywords

Hospital-Acquired Pneumonia, Gram Negative Bacteria

Brief summary

Nebulized Colistin for Adjunctive Therapy of Hospital-Acquired Pneumonia caused by Gram Negative Bacteria should be more effective than conventional therapy

Detailed description

Randomized Controlled Clinical Trial in hospitalized adult patients with hospital-acquired pneumonia. The patients are allocated to conventional group or nebulized colistin group. The conventional group receives conventional antibiotics whereas the nebulized colistin group receives nebulized colistin in addition to conventional antibiotics. The outcomes are clinical response and microbiological responses.

Interventions

DRUGnebulized colistin

nebulized colistin 75 mg every 12 hours

DRUGantibiotics

conventional parenteral antibiotics

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (age\>18 years) hospitalized patient with hospital-acquired pneumonia due to Gram negative bacteria

Exclusion criteria

* pregnancy * lactating woman * colistin allergy * severe renal impairment * epilepsy

Design outcomes

Primary

MeasureTime frame
Clinical response14 days after Treatment

Secondary

MeasureTime frame
Microbiological response and safety14 days after treatment

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026